Glaucoma is a progressive disease resulting in blindness. Determining the onset of the
disease, predicting its severity and the benefit of pressure lowering eye drops is key to
clinical management aimed at maintaining useful vision with advancing age. This study will
longitudinally monitor a population of glaucoma suspects (with positive factors for the
disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other
standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells
(RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before
dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with
abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG
will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography
(OCT) and other ancillary tests every 6 months over 4 years.